Vaccination against COVID-19: understanding the past and present and designing the future

• Grant number: 22/11981-1
• Support Opportunities: Research Grants - Visiting Researcher Grant - Brazil
• Start date: March 01, 2023
• End date: February 29, 2024
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal Investigator: Luis Carlos de Souza Ferreira
• Grantee: Luis Carlos de Souza Ferreira
• Visiting researcher: Jaime Henrique Amorim Santos
• Visiting researcher institution: Universidade Federal do Oeste da Bahia (UFOB). Centro das Ciências Biológicas e da Saúde (CCBS) , Brazil
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• City of the host institution: São Paulo

Abstract

SARS-CoV-2 has become a threat to global public health, by breaking a barrier between the species of acute human syndromes and causing a type of acute infection that is highly transmissible between humans, called COVID-19, and is distributed around the world, with serious intent in a pandemic. The offer of high genetic studies for vaccines vaccines for use in the main glycoprotein at the moment, identifies the envelope of this offer of studies of high update of vaccines for viral knowledge in the coming years. The project developed for this purpose is to develop vaccines for the purpose of this COVID2 is to develop vaccines for the purpose of this COVID2. This goal must be met through two approaches, a clinical study observe where the population will be evaluated, Bahia, a set of qualities for qualities for quality and immunoii) , a computational study to identify promissory notes that could be modified in a modified response - against SARS - result of a genetic modification V of escape genetic modification. The project has strong funding and an execution team. It is expected that the genetics of the two approaches will generate information for the proposition and development of innovative vaccine antigens, with long-term application, in view of the high anti-virus treatment capacity of the virus that causes COVID-19. (AU)